Edgewise Therapeutics

Biotech & Life Sciences · Boulder, United States · Founded 2017 · IPO 2021

Edgewise Therapeutics is a biotechnology company focused on developing innovative therapies for rare muscle disorders such as Duchenne, Becker, and Limb Girdle muscular dystrophies, as well as McArdle disease. Utilizing a proprietary drug discovery platform, the company aims to create a holistic therapeutic approach to protect muscle health. Edgewise Therapeutics serves patients and families affected by these progressive muscle disorders, operating within the niche market of precision medicine for rare diseases. The business model involves retaining global development and commercialization rights to its programs, allowing for strategic collaborations and asset acquisitions to accelerate development and expand its pipeline. Revenue is generated through the development and commercialization of its lead molecule, sevasemten (EDG 5506), which targets the muscle motor protein myosin to reduce stress in fast skeletal muscle fibers without affecting other muscle types. Keywords: biotechnology, rare muscle disorders, Duchenne, Becker, Limb Girdle, McArdle disease, precision medicine, drug discovery, sevasemten, myosin, muscle health.

Valuation $3.64B

Revenue $209M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Featured in

News Edgewise sells muscular dystrophy drug to Servier for up to $2.65B Jun 2, 2026

Investors

20 investors on Edgewise Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

U.S. Venture Partners

Novo Seeds

Novo Ventures

Series B+ 17 investors entered at this stage

Viking Global Investors

New Leaf Venture Partners

OrbiMed

Janus Henderson Investors

Wellington Management

Citadel

Logos Capital

Novo Holdings

Deerfield

Cormorant Asset Management

RA Capital Management

Cure Duchenne

Surveyor Capital

TCGX

Frazier Life Sciences

Perceptive Advisors

Venrock Healthcare Capital Partners

Global footprint

Where Edgewise Therapeutics has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States96.9%

🇬🇧 United Kingdom2.3%

🇨🇭 Switzerland0.8%

3 countries shown

Web traffic by country

13K monthly visits
across markets

🇺🇸 United States83.8%

🇮🇳 India10%

🇬🇧 United Kingdom3.8%

🇵🇭 Philippines1.5%

🇫🇷 France0.8%

Top 5 markets shown

Talent graph

The shape of Edgewise Therapeutics's talent

Dealroom maps Edgewise Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 team members profilednamed & role-tagged by Dealroom

154 employeestotal headcount

7 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Edgewise Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$11M patent portfolio · 14 active families

Estimated portfolio value

$11M

0.30% of market cap · 30.5× smaller than top peer Translate Bio ($336M)

14 active patent families

Where Edgewise Therapeutics innovates Cardio vascular diseaseMyosinObesityObstructive sleep apneaOsteo arthritis

Where Edgewise Therapeutics concentrates vs peers

Each axis is a top-10 topic across Edgewise Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Edgewise Therapeutics

An AI-synthesized read of the highest-engagement posts about Edgewise Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Edgewise Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles